|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Stock Screener |
Insider Trading Graph View |
Insider Watch |
Insider Trading - Intellia Therapeutics Inc. (NTLA)
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2018-06-19 Sale |
2018-06-20 12:03 pm |
Intellia Therapeutics Inc. | NTLA | FORMELA JEAN FRANCOIS Director |
6,686 | $27.96 | $186,908 | 1,836,810 (Indirect) |
View |
| 2018-05-16 Sale |
2018-05-17 10:47 am |
Intellia Therapeutics Inc. | NTLA | FORMELA JEAN FRANCOIS Director |
6,686 | $25.04 | $167,389 | 2,058,299 (Indirect) |
View |
| 2018-05-14 Sale |
2018-05-15 8:43 pm |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M. CEO |
8,400 | $24 | $201,600 | 467,352 (Direct Indirect) |
View |
| 2018-03-20 Sale |
2018-03-22 1:43 pm |
Intellia Therapeutics Inc. | NTLA | FORMELA JEAN FRANCOIS Director |
39,245 | $23.87 | $936,743 | 2,279,788 (Indirect) |
View |
| 2018-01-29 Sale |
2018-01-30 5:28 pm |
Intellia Therapeutics Inc. | NTLA | Caribou Biosciences Inc. 10% Owner |
550,645 | $26.78 | $14,746,273 | 3,994,355 (Indirect) |
View |
| 2017-12-12 Sale |
2017-12-14 12:19 pm |
Intellia Therapeutics Inc. | NTLA | Novartis Institutes for BioMedical Research Inc. NOVARTIS AG 10% Owner |
1,523,000 | $18.3 | $27,870,899 | 4,129,903 (Direct) |
View |
| 2017-12-06 Sale |
2017-12-08 5:27 pm |
Intellia Therapeutics Inc. | NTLA | Bermingham Nessan CEO |
336,783 | $20.78 | $7,000,019 | 696,000 (Direct) |
View |
| 2017-09-13 Sale |
2017-09-13 6:29 pm |
Intellia Therapeutics Inc. | NTLA | Caribou Biosciences Inc. 10% Owner |
1,048,846 | $0 | $0 | 4,545,000 (Indirect) |
View |
| 2017-07-07 Sale |
2017-07-11 5:40 pm |
Intellia Therapeutics Inc. | NTLA | FORMELA JEAN FRANCOIS Director |
150,000 | $16.24 | $2,435,440 | 3,699,788 (Indirect) |
View |
| 2017-07-07 Sale |
2017-07-11 5:37 pm |
Intellia Therapeutics Inc. | NTLA | Atlas Venture Fund IX L.P. Atlas Venture Associates IX L.P. Atlas Venture Associates IX LLC 10% Owner |
150,000 | $16.24 | $2,435,440 | 3,699,788 (Direct) |
View |
| 2017-03-09 Sale |
2017-03-13 10:39 am |
Intellia Therapeutics Inc. | NTLA | Atlas Venture Associates IX L.P. Atlas Venture Associates IX LLC 10% Owner |
21,132 | $13.91 | $293,843 | 3,729,788 (Indirect Direct) |
View |
| 2017-03-09 Sale |
2017-03-13 10:34 am |
Intellia Therapeutics Inc. | NTLA | FORMELA JEAN FRANCOIS Director |
21,132 | $13.91 | $293,843 | 3,729,788 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2018-05-17 Option Award |
2018-05-21 12:59 pm |
N/A 2028-05-16 |
Intellia Therapeutics Inc. | NTLA | FORMELA JEAN FRANCOIS Director |
19,000 | $25.98 | 19,000 (Direct) |
View |
| 2018-05-17 Option Award |
2018-05-21 12:56 pm |
N/A 2028-05-16 |
Intellia Therapeutics Inc. | NTLA | KARSEN PERRY A Director |
19,000 | $25.98 | 19,000 (Direct) |
View |
| 2018-05-17 Option Award |
2018-05-21 12:54 pm |
N/A 2028-05-16 |
Intellia Therapeutics Inc. | NTLA | DORSA CAROLINE Director |
19,000 | $25.98 | 19,000 (Direct) |
View |
| 2018-05-17 Option Award |
2018-05-21 12:51 pm |
N/A 2028-05-16 |
Intellia Therapeutics Inc. | NTLA | Verwiel Frank Director |
19,000 | $25.98 | 19,000 (Direct) |
View |
| 2018-05-01 Option Award |
2018-05-02 4:35 pm |
N/A 2028-04-30 |
Intellia Therapeutics Inc. | NTLA | SCHIERMEIER ANDREW VP |
23,500 | $20.56 | 23,500 (Direct) |
View |
| 2018-03-28 Exercise |
2018-03-30 10:20 am |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Bell Graeme CFO |
8,000 | $13.48 | 202,000 (Direct) |
View |
| 2018-03-28 Exercise |
2018-03-30 10:20 am |
N/A 2027-01-02 |
Intellia Therapeutics Inc. | NTLA | Bell Graeme CFO |
8,000 | $13.48 | 202,000 (Direct) |
View |
| 2018-03-23 Option Award |
2018-03-26 5:12 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | DORSA CAROLINE Director |
410 | $24.05 | 5,410 (Direct) |
View |
| 2018-01-25 Option Award |
2018-01-29 3:32 pm |
N/A 2028-01-24 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M. CEO |
220,000 | $22.78 | 220,000 (Direct) |
View |
| 2018-01-25 Option Award |
2018-01-29 3:31 pm |
N/A 2028-01-24 |
Intellia Therapeutics Inc. | NTLA | Bell Graeme CFO |
25,000 | $22.78 | 25,000 (Direct) |
View |
| 2018-01-25 Option Award |
2018-01-29 3:30 pm |
N/A 2028-01-24 |
Intellia Therapeutics Inc. | NTLA | Rivera Jose E VP |
25,000 | $22.78 | 25,000 (Direct) |
View |
| 2017-12-12 Option Award |
2017-12-14 4:08 pm |
N/A 2027-12-11 |
Intellia Therapeutics Inc. | NTLA | Rivera Jose E VP |
72,500 | $18.3 | 72,500 (Direct) |
View |
| 2017-12-12 Option Award |
2017-12-14 4:08 pm |
N/A 2027-12-11 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M. VP |
72,500 | $18.3 | 72,500 (Direct) |
View |
| 2017-12-12 Option Award |
2017-12-14 4:07 pm |
N/A 2027-12-11 |
Intellia Therapeutics Inc. | NTLA | Bermingham Nessan CEO |
292,500 | $18.3 | 292,500 (Direct) |
View |
| 2017-12-12 Option Award |
2017-12-14 4:06 pm |
N/A 2027-12-11 |
Intellia Therapeutics Inc. | NTLA | Bell Graeme CFO |
72,500 | $18.3 | 72,500 (Direct) |
View |
| 2017-11-03 Option Award |
2017-11-03 11:54 am |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Bell Graeme CFO |
5,000 | $22.04 | 13,400 (Direct) |
View |
| 2017-07-25 Option Award |
2017-07-25 4:49 pm |
N/A 2027-07-24 |
Intellia Therapeutics Inc. | NTLA | Verwiel Frank Director |
38,000 | $16.91 | 38,000 (Direct) |
View |
| 2017-07-25 Option Award |
2017-07-25 4:47 pm |
N/A 2027-07-24 |
Intellia Therapeutics Inc. | NTLA | Slaoui Moncef Director |
38,000 | $16.91 | 38,000 (Direct) |
View |
| 2016-06-02 Option Award |
2017-06-05 08:03 am |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | DORSA CAROLINE Director |
5,000 | $12.42 | 5,000 (Direct) |
View |
| 2017-06-01 Option Award |
2017-06-05 08:01 am |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | KARSEN PERRY A Director |
5,000 | $11.98 | 5,000 (Direct) |
View |
| 2017-06-02 Option Award |
2017-06-05 07:59 am |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Bell Graeme CFO |
8,400 | $12.37 | 8,400 (Direct) |
View |
| 2017-06-01 Option Award |
2017-06-05 07:57 am |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Rivera Jose E VP |
8,400 | $12.03 | 262,210 (Direct) |
View |
| 2017-06-01 Option Award |
2017-06-05 07:55 am |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M. VP |
7,800 | $12.06 | 466,408 (Indirect) |
View |
| 2017-06-01 Option Award |
2017-06-05 07:55 am |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M. VP |
600 | $12.09 | 466,408 (Indirect) |
View |
| 2017-06-01 Option Award |
2017-06-05 07:53 am |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Bermingham Nessan CEO |
8,400 | $11.95 | 795,033 (Direct) |
View |
| 2017-05-18 Option Award |
2017-05-19 5:14 pm |
N/A 2027-05-17 |
Intellia Therapeutics Inc. | NTLA | DORSA CAROLINE Director |
19,000 | $14.35 | 19,000 (Direct) |
View |
| 2017-05-18 Option Award |
2017-05-19 5:12 pm |
N/A 2027-05-17 |
Intellia Therapeutics Inc. | NTLA | FORMELA JEAN FRANCOIS Director |
19,000 | $14.35 | 19,000 (Direct) |
View |
| 2017-05-18 Option Award |
2017-05-19 5:10 pm |
N/A 2027-05-17 |
Intellia Therapeutics Inc. | NTLA | GORDON CARL L Director |
19,000 | $14.35 | 19,000 (Direct) |
View |
| 2017-05-18 Option Award |
2017-05-19 5:08 pm |
N/A 2027-05-17 |
Intellia Therapeutics Inc. | NTLA | KARSEN PERRY A Director |
19,000 | $14.35 | 19,000 (Direct) |
View |
| 2017-03-03 Other |
2017-03-07 3:11 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Novartis Institutes for BioMedical Research Inc. NOVARTIS AG 10% Owner |
79,245 | $0 | 5,652,903 (Direct) |
View |
|
© 2005-2018 SecForm4.Com All rights reserved. Archives: 2018 2017 2016 2015 2014 2013 ... Wed, 20 Jun 2018 11:50:39 -0500 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |